|
Press Releases |
|
 |
|
Wednesday, March 23, 2022 |
|
Alset International Ltd establishes Alset Mining Pte Ltd to embark on cryptocurrency mining activities |
Singapore Exchange-listed Alset International Ltd (SGX Stock Code: 40V) ("Alset", the "Company" or together with its subsidiaries, the "Group) wishes to announce that the Company has plans to embark on cryptocurrency mining business through its subsidiary Alset Mining Pte. Ltd. ("Alset Mining"). more info >> |
|
Monday, February 21, 2022 |
|
Alset Capital Acquisition Corp. Announces Closing of Initial Public Offering and Exercise of Full Over-Allotment Option |
Alset Capital Acquisition Corp. (the "Company") announced on February 3, 2022 the closing of its initial public offering of 7,500,000 units at $10.00 per unit (the "Offering"). more info >> |
|
Monday, October 5, 2020 |
|
Impact BioMedical to Begin Efficacy Testing Pan-Coronavirus Vaccine Under New Wholly Owned Subsidiary Innate Immune, Inc. |
Document Security Systems, Inc. today announced its wholly owned subsidiary Impact BioMedical, Inc. ("Impact BioMedical") has formed a new wholly owned subsidiary, Innate Immune, Inc. ("Innate Immune"), to initiate efficacy testing of a pancoronavirus vaccine, a special type of vaccine designed to protect against multiple coronaviruses. more info >> |
|
Friday, September 18, 2020 |
|
Impact BioMedical Demonstrates 10-Fold Reduction in Viral Population of COVID-19 in Surface Disinfectant Efficacy Testing of its 3F Antiviral Biofragrance |
Document Security Systems, Inc. (NYSE American: DSS) today announced its wholly owned subsidiary Impact BioMedical, Inc., through its subsidiary Global BioLife, Inc., completed efficacy testing of its proprietary 3F Antiviral Biofragrance at a biosafety level 3 containment facility at an independent university. more info >> |
|
Friday, July 31, 2020 |
|
Impact Biomedical initiates Quantum, a new frontier in Pharmaceutical Development |
SGX-listed Singapore eDevelopment Limited's (SeD; SGX:40V) wholly-owned subsidiary Impact Biomedical Inc. ("Impact"), announced today the initiation of Quantum, their research program designed to solve the impending pharmaceutical patent cliff threat. more info >> |
|
Wednesday, June 24, 2020 |
|
Impact Biomedical Achieves COVID-19 Success with Equivir and 3F Biofragrance |
SGX-listed Singapore eDevelopment Limited's (SeD; SGX:40V) wholly owned subsidiary Impact Biomedical Inc. ("Impact Biomedical") announced today that they proved in vitro success of Equivir and 3F Biofragrance against COVID-19 in independent laboratory testing. more info >> |
|
Wednesday, June 17, 2020 |
|
Impact Biomedical Announces Publication of COVID-19 Research in Peer-Reviewed Journal |
SGX-listed Singapore eDevelopment Limited's (SeD; SGX:40V) wholly owned subsidiary Impact Biomedical Inc. ("Impact Biomedical") announced today that their COVID-19 research with Global Research and Discovery Group Sciences ("GRDG"), conducted in collaboration with Harvard Medical School and Vilotos Pharmaceutical, Inc. ("Vilotos"), was published in the peer-reviewed scientific journal Molecules on June 11, 2020. more info >> |
|
Monday, June 1, 2020 |
|
Impact Biomedical and GRDG Sciences Announce Medical Technology Package Valued at USD 1.39 Billion (SGD 1.97 Billion) by Independent Experts |
SGX-listed Singapore eDevelopment Limited's (SeD; SGX:40V) wholly owned subsidiary, Impact Biomedical Inc., would like to update its stakeholders on its suite of antiviral and medical technologies. more info >> |
|
Friday, April 24, 2020 |
|
Impact Biomedical's Majority Owned Next Generation Medical Technologies Valued at USD 592 Million (SGD 841 Million) by Independent Experts |
SGX-listed Singapore eDevelopment Ltd's (SeD; SGX:40V) wholly owned subsidiary Impact Biomedical Inc., announced recently that their suite of antiviral and medical technologies, co-owned with its partners, is valued at USD 592 Million (SGD 841 Million). Impact Biomedical's effective ownership of 64.53% in the suite of technologies equates to a value of USD 382 Million (SGD 542 Million). more info >> |
|
Wednesday, March 18, 2020 |
|
Impact BioMedical's Linebacker and Equivir inhibit SARS-CoV-2, virus responsible for the COVID-19 outbreak |
Singapore Exchange-listed Singapore eDevelopment Limited has announced that its wholly-owned U.S. biomedical subsidiary, Impact BioMedical, Inc., has, through its scientific research partner, GRDG Sciences, LLC. ("GRDG"), recently conducted molecular docking studies, utilizing advanced computational models, which indicate Linebacker and Equivir successfully inhibit infection of SARS-CoV-2, the virus responsible for the COVID-19 outbreak. more info >> |
|
|
|
|
|
|
|
|
Latest Press Releases |
|
BW Digital and BW ESS launch BW Velora to drive greater digital sustainability
Jun 23, 2025 00:17 HKT/SGT
|
|
|
New method to blend functions for soft electronics
Jun 23, 2025 00:15 HKT/SGT
|
|
|
「數字經濟新引擎:以新質生產力推動數字文旅新產業」
Jun 22, 2025 23:01 HKT/SGT
|
|
|
U Power宣佈在香港投建55座智能換電站 香港首座示範運營智能換電站正式落成
Jun 21, 2025 20:22 HKT/SGT
|
|
|
U Power宣布在香港兴建55座智能换电站 香港首座示范营运智能换电站正式落成
Jun 21, 2025 18:32 HKT/SGT
|
|
|
「数字经济新引擎:以新质生产力推动数字文旅新产业」
Jun 21, 2025 17:09 HKT/SGT
|
|
|
康希諾重磅推出優佩欣疫苗 為兒童健康保駕護航的創新之選
Jun 21, 2025 12:09 HKT/SGT
|
|
|
塑造全球增長新平台 - SPIEF-2025開放對話討論
Jun 21, 2025 09:48 HKT/SGT
|
|
|
塑造全球增长新平台 - SPIEF-2025开放对话讨论
Jun 21, 2025 09:34 HKT/SGT
|
|
|
Ditchit Detonates Iconic Twitter Bird to Symbolize Launch of Local Marketplace
Jun 21, 2025 06:00 HKT/SGT
|
|
|
Shaping a New Platform for Global Growth Discussed at Open Dialogue within SPIEF-2025
Jun 20, 2025 23:00: JST
|
|
|
Shaping a New Platform for Global Growth Discussed at Open Dialogue within SPIEF-2025
Jun 20, 2025 23:00 HKT/SGT
|
|
|
Shaping a New Platform for Global Growth がSPIEF-2025のオープンダイアログで議論される
Jun 20, 2025 23:00: JST
|
|
|
Global Economic Shifts in Focus as Madrid Professor Addresses SPIEF 2025 Opening Session
Jun 20, 2025 23:00: JST
|
|
|
Global Economic Shifts in Focus as Madrid Professor Addresses SPIEF 2025 Opening Session
Jun 20, 2025 23:00 HKT/SGT
|
|
|
|
More News >> |
|
|
|
|
|